Kiniksa Pharma Files Proxy Materials

TL;DR

Kiniksa Pharma filed proxy docs, get ready for shareholder votes.

AI Summary

Kiniksa Pharmaceuticals International, plc filed a Definitive Additional Materials proxy statement on May 9, 2025. This filing relates to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company is incorporated in X0 and its fiscal year ends on December 31st.

Why It Matters

This filing indicates that Kiniksa Pharmaceuticals is proceeding with corporate governance procedures, likely involving shareholder votes on important company decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would immediately impact risk.

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Registrant
• 0001104659-25-046775 (filing_id) — Accession Number
• 20250509 (date) — Filing Date
• DEFA14A (document_type) — Form Type
• 2834 (sic_code) — Standard Industrial Classification
• 7814319100 (phone_number) — Business Phone

FAQ

From the Filing

0001104659-25-046775.txt : 20250509 0001104659-25-046775.hdr.sgml : 20250509 20250509163209 ACCESSION NUMBER: 0001104659-25-046775 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 19 FILED AS OF DATE: 20250509 DATE AS OF CHANGE: 20250509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25930990 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 DEFA14A 1 tm2514322-2_defa14a.htm DEFA14A tm2514322-1_nonfiling - none - 2.5312707s ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒    Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ☐ Definitive Proxy Statement ​ ☒ Definitive Additional Materials ​ ☐ Soliciting Material Under §240.14a-12 ​ KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC ​ (Name of Registrant as Specified in its Charter)     ​ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) ​ Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ​ ☐ Fee paid previously with preliminary materials. ​ ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. ​   ​ Supplement to the Definitive Proxy Statement for the 2025 Annual Meeting of Shareholders to be Held on June 3, 2025 EXPLANATORY NOTE On April 21, 2025, Kiniksa Pharmaceuticals International, plc (the “ Company ”, “ we ,” “ us ,” or “ our ”) filed a definitive proxy statement (the “ Proxy Statement ”) with the Securities and Exchange Commission (the “ SEC ”), which was distributed in connection with our 2025 Annual Meeting of Shareholders to be held on June 3, 2025 at 3:00 p.m. British Summer Time (10:00 a.m. Eastern Daylight Time) at Third Floor, 23 Old Bond Street, London, United Kingdom W1S 4PZ (the “ Annual Meeting ”). Due to an administrative error, the Summary Compensation Table included in the “Executive Compensation” section of the Proxy Statement inadvertently omitted certain components of Ross Moat’s compensation, including a car allowance, a cash relocation allowance (including an associated tax gross-up), payments for accrued but unused vacation time made in connection with Mr. Moat’s change in primary work location and certain aircraft flights for Mr. Moat and his family (including associated tax gross-ups). Mr. Moat served as the Company’s Chief Commercial Officer in each of 2022, 2023 and 2024 and was a named executive officer of the Company in 2024. The information for 2024 in the “Pay versus Performance” section of the Proxy Statement that is based on the Summary Compensation Table has also been updated to reflect the compensation described above. This proxy statement supplement, dated May 9, 2025 (the “ Supplement ”), supplements and amends the Proxy Statement and is being filed to correct the errors described above by: • Reproducing th